Advances in the use of EGFR TKIs in the Treatment of NSCLC

46.3K

views

145

authors

21

articles

Editorial

31 October 2024

Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC

Paola Ulivi

738 views

0 citations

Editors

3

Laboratory of Biosciences, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS)

National Cancer Center Hospital

Santiago Viteri

UOMI Cancer Center. Clínica Mi Tres Torres

Impact

Fetching...

About

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all cases. Over the last decade, there have been significant advances in the treatment of NSCLC, particularly with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR is a key driver of NSCLC, and EGFR TKIs have shown remarkable clinical activity in patients with EGFR-mutant NSCLC.

Despite these advances, however, there are still many unanswered questions regarding the optimal use of EGFR TKIs in the treatment of NSCLC. To improve patient outcomes, further research into the use of EGFR TKIs in lung cancer therapy is vital. Our goal is to provide an overview of the latest advances in the use of EGFR TKIs in the treatment of NSCLC.

This Research Topic aims to provide a comprehensive overview of the latest advances in the use of EGFR TKIs in the treatment of NSCLC, with the ultimate goal of improving patient outcomes. We welcome original research articles, reviews, and perspectives from experts in the field, focusing on, but not limited to the following:

- Preclinical or clinical studies that provide new insights into the use of EGFR TKIs in the treatment of NSCLC.

- Mechanisms of resistance to EGFR TKI therapy and new treatment strategies for NSCLC patients with acquired resistance to EGFR TKIs

- The role of combination therapies.

- Perspectives may offer expert opinions on the future of EGFR TKI therapy and potential directions for future research.

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all cases. Over the last decade, there have been significant advances in the treatment of NSCLC, particularly with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR is a key driver of NSCLC, and EGFR TKIs have shown remarkable clinical activity in patients with EGFR-mutant NSCLC.

Despite these advances, however, there are still many unanswered questions regarding the optimal use of EGFR TKIs in the treatment of NSCLC. To improve patient outcomes, further research into the use of EGFR TKIs in lung cancer therapy is vital. Our goal is to provide an overview of the latest advances in the use of EGFR TKIs in the treatment of NSCLC.

This Research Topic aims to provide a comprehensive overview of the latest advances in the use of EGFR TKIs in the treatment of NSCLC, with the ultimate goal of improving patient outcomes. We welcome original research articles, reviews, and perspectives from experts in the field, focusing on, but not limited to the following:

- Preclinical or clinical studies that provide new insights into the use of EGFR TKIs in the treatment of NSCLC.

- Mechanisms of resistance to EGFR TKI therapy and new treatment strategies for NSCLC patients with acquired resistance to EGFR TKIs

- The role of combination therapies.

- Perspectives may offer expert opinions on the future of EGFR TKI therapy and potential directions for future research.

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Download ebook

Share

Editors

Laboratory of Biosciences, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS)

National Cancer Center Hospital

Santiago Viteri

UOMI Cancer Center. Clínica Mi Tres Torres

Impact

46,274 Total views

30,613 Article views

14,805 Article downloads

856 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Thoracic Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic